TGFβ1 and SMAD3 Expression Are Associated With Survival After the Immune Checkpoint Inhibitor Therapy for Small Cell Lung Cancer
Cancer Reports · 2025
DOI: 10.1002/cnr2.70394 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Reports, 2025. Verfasst von Zenta Seto und 12 weiteren Autor:innen. Beteiligte Einrichtung: First Department of Internal Medicine, Toyama University Hospital, Toyama, Japan. Hauptthemen laut MEDLINE: Smad3 Protein, Lung Neoplasms, Small Cell Lung Carcinoma, Transforming Growth Factor beta1. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Tumor immunity is involved in the progression of malignant tumors. However, there are few reports on the relationship between the immunological environment and the efficacy of immune checkpoint inhibitors in small cell lung cancer (SCLC). We analyzed the relationship between tumor‐infiltrating immune cells and protein expression and survival in patients with SCLC treated with combined therapy with immune checkpoint inhibitors plus chemotherapy.
Methods
Patients with SCLC who received combined therapy with immune checkpoint inhibitors plus chemotherapy between 2019 and 2023 were enrolled. Immune cell infiltration levels, including CD4, CD8, FOXP3, CD163‐positive cells and expression levels of TGFβ1 and SMAD3 proteins in tumor tissue were evaluated by immunohistochemistry. Progression‐free survival (PFS) and overall survival (OS) were evaluated as endpoints.
Results
Data from 22 patients were analyzed. The high CD4‐positive T lymphocyte ( p = 0.008, log‐rank test) and the high CD8‐positive T lymphocyte infiltration group ( p = 0.031, log‐rank test) showed statistically significantly longer OS than the low infiltration group. On the other hand, the low TGFβ1 expression group showed significantly longer PFS ( p = 0.026, log‐rank test) and the low SMAD3 expression group showed significantly longer OS ( p = 0.042, log‐rank test) than the high expression group.
Conclusion
In conclusion, it is suggested that infiltration of T lymphocytes and expression of TGFβ1 and SMAD3 may be related to the efficacy of the combined therapy with immune checkpoint inhibitors plus chemotherapy in patients with SCLC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- First Department of Internal Medicine, Toyama University Hospital, Toyama, Japan.
- Department of Diagnostic Pathology, Faculty of Medicine, Academic Assembly, University of Toyama, Toyama, Japan.
- Department of Clinical Oncology, Toyama University Hospital, Toyama, Japan.
ORCID-Profile: Minehiko Inomata, Akira Noguchi, Tomonobu Kado, Seisuke Okazawa, Ryuji Hayashi, Kenichi Hirabayashi, Kazuyuki Tobe
Zitieren
APA
Seto, Z., Inomata, M., Noguchi, A., Kado, T., Murayama, N., Takata, N., Tokui, K., Okazawa, S., Imanishi, S., Miwa, T., Hayashi, R., Hirabayashi, K., & Tobe, K. (2025). TGFβ1 and SMAD3 Expression Are Associated With Survival After the Immune Checkpoint Inhibitor Therapy for Small Cell Lung Cancer. Cancer Reports. https://doi.org/10.1002/cnr2.70394
Vancouver
Seto Z, Inomata M, Noguchi A, Kado T, Murayama N, Takata N, et al. TGFβ1 and SMAD3 Expression Are Associated With Survival After the Immune Checkpoint Inhibitor Therapy for Small Cell Lung Cancer. Cancer Reports. 2025. doi:10.1002/cnr2.70394
BibTeX
@article{Seto2025,
author = {Seto, Zenta and Inomata, Minehiko and Noguchi, Akira and Kado, Tomonobu and Murayama, Nozomu and Takata, Naoki and Tokui, Kotaro and Okazawa, Seisuke and Imanishi, Shingo and Miwa, Tosihiro and Hayashi, Ryuji and Hirabayashi, Kenichi and Tobe, Kazuyuki},
title = {TGFβ1 and SMAD3 Expression Are Associated With Survival After the Immune Checkpoint Inhibitor Therapy for Small Cell Lung Cancer},
journal = {Cancer Reports},
year = {2025},
doi = {10.1002/cnr2.70394}
}
EUVIMED